Harrow (HROW) | Stock Overview & Key Data
Harrow Performance Comparison
Stock Range
Today's Range
Low: $38.34
High: $40.41
on August 22, 2025
52 Week Range
Low: $20.85
High: $59.23
on April 9, 2025
on October 18, 2024
All-Time High: $140.00 on October 1, 2007
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.4B
EPS
-0.28
P/E Ratio (TTM)
-78.02
Forward P/E
37.35
P/B Ratio
28.45
PEG Ratio
0.44
Div. Yield
N/A
ROE
-19.03%
Beta
0.410
Debt to Equity
469.08
Financial Highlights
Profitability
Gross Margin
74.54%
Operating Margin
17.90%
Profit Margin
-4.49%
Returns and Earnings
Return on Assets (TTM)
2.81%
Return on Equity (TTM)
-19.03%
EBITDA
$23.4M
Net Income (TTM)
$-10.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$6.39
Quarterly Revenue Growth (YoY)
30.20%
Quarterly Earnings Growth (YoY)
30.25%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Harrow HROW | 1.42B Small-cap | -4.62% | 2.91% | 42.76% | 31.81% | 4.38% | -10.63% | 314.33% | 445.14% |
| Zoetis ZTS | 65.30B Large-cap | 4.59% | 0.82% | -3.89% | -1.51% | -5.23% | -16.11% | -9.09% | -2.69% |
| Haleon Plc - ADR HLN | 43.42B Large-cap | 1.13% | 2.94% | -11.62% | -2.68% | 3.92% | -0.91% | 57.46% | 32.39% |
| Ani Pharmaceuticals ANIP | 1.90B Small-cap | 1.27% | 39.34% | 54.27% | 57.30% | 64.39% | 47.76% | 139.84% | 191.55% |
| BioCryst BCRX | 1.76B Small-cap | -0.83% | -1.64% | -16.78% | -9.01% | 7.02% | 3.46% | -41.23% | 111.08% |
| BGM BGM | 1.55B Small-cap | -0.66% | -29.26% | -39.11% | -23.34% | -15.88% | 28.55% | 24.30% | -82.81% |
Ownership & Short Interest
Insider Ownership
15.72%
Institutional Ownership
57.32%
Shares Short
5M
Short Ratio
10.05
Short % of Shares Outstanding
15.51%
Average 10-Day Volume
812K
Average 90-Day Volume
585K
Harrow Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Harrow would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is HROW's 52-week high and low?
- In the last 52 weeks, Harrow reached a high of $59.23 (on October 18, 2024) and a low of $20.85 (on April 9, 2025).
- What is the market cap and P/E ratio for HROW?
- Curious about Harrow's size and valuation? Its market capitalization stands at 1.42B. When it comes to valuation, the P/E ratio (trailing twelve months) is -78.02, and the forward P/E (looking ahead) is 37.35.
- Does HROW pay dividends? If so, what's the yield?
- As for dividends, Harrow isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Harrow's main competitors or similar companies to consider before investing?
When looking at Harrow, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS65.30B Healthcare Drug Manufacturers - Specialty & Generic -16.11% -9.09% Haleon Plc - ADR
HLN43.42B Healthcare Drug Manufacturers - Specialty & Generic -0.91% 57.46% Ani Pharmaceuticals
ANIP1.90B Healthcare Drug Manufacturers - Specialty & Generic 47.76% 139.84% BioCryst
BCRX1.76B Healthcare Drug Manufacturers - Specialty & Generic 3.46% -41.23% BGM
BGM1.55B Healthcare Drug Manufacturers - Specialty & Generic 28.55% 24.30% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Harrow Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Harrow's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -19.03%, the Debt to Equity ratio from the most recent quarter is 469.08, and its Gross Profit Margin stands at 74.54%.
- What is the recent revenue and earnings growth for HROW?
- Looking at Harrow's growth, its revenue over the trailing twelve months (TTM) was $228M. Compared to the same quarter last year (YoY), quarterly revenue grew by 30.20%, and quarterly earnings saw a YoY growth of 30.25%.
- How much of HROW stock is held by insiders and institutions?
- Wondering who owns Harrow stock? Company insiders (like executives and directors) hold about 15.72% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 57.32%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.